Designing nanomaterials for the delivery of antiparasitic drugs
Source abstract
Abstract
Parasitic infections continue to pose significant public health challenges worldwide. Most traditional antiparasitic drugs face severe resistance issues owing to their extensive use. Moreover, they are limited by low bioavailability, inferior targeting efficiency, and rapid elimination from the body. Consequently, the overuse of drugs and subsequent toxic side effects are inevitable. In this regard, nanomaterials have emerged as promising drug carriers. Given their ability to target drug delivery, overcome biological barriers, and degrade biologically, nanomaterials can improve drug pharmacokinetics while maintaining low toxicity. Although nanomedicine delivery systems have demonstrated outstanding advantages in vitro and in vivo , comprehensive reviews in this area are scarce. This is primarily because the application of these systems for parasitic infections remains critically under-represented in clinical studies. Key aspects—such as long-term biocompatibility, scalable manufacturing, cost-effectiveness, and safety across diverse endemic populations—are yet to be systematically validated. This review comprehensively discusses recent developments in nanomaterials as drug carriers, explores the applications of nanomaterials in the delivery of antiparasitic drugs, highlights advanced design strategies (such as stimuli-responsive and synergistic therapies) for enhanced efficacy, and analyzes the challenges and future directions of nano-drug delivery systems. We believe that this review will provide a scientific basis for further control and treatment of parasitic diseases.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticles: synthesis and applications · Nanoparticle-Based Drug Delivery · Parasitic Infections and Diagnostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Malaria: biology and disease10.1016/j.cell.2016.07.055 ↗
2. Ancient plasmodium genomes shed light on the history of human malaria10.1038/s41586-024-07546-2 ↗
3. Nanotechnology-based strategies in parasitic disease management: from prevention to diagnosis and treatment10.1021/acsomega.3c04587 ↗
4. Zoonotic helminths – why the challenge remains10.1017/S0022149X23000020 ↗
5. Nanomedicine approaches against parasitic worm infections10.1002/adhm.201701494 ↗
6. Understanding pathogen survival and transmission by arthropod vectors to prevent human disease10.1126/science.abc2757 ↗
7. An overview of drug resistance in protozoal diseases10.3390/ijms20225748 ↗
8. Evolution of partial resistance to artemisinins in malaria parasites in Uganda10.1056/NEJMoa2211803 ↗
9. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic10.1038/nm.4381 ↗
10. Evaluations of candidate markers of dihydroartemisinin-piperaquine resistance in Plasmodium falciparum isolates from the China–Myanmar, Thailand–Myanmar, and Thailand–Cambodia borders10.1186/s13071-022-05239-1 ↗
11. Alternative first-line malaria treatment10.4103/aam.aam_35_23 ↗
12. First report of anthelmintic resistance in gastrointestinal nematodes in goats in Romania10.3390/ani11102761 ↗
13. The first report of multidrug resistance in gastrointestinal nematodes in goat population in Poland10.1186/s12917-020-02501-5 ↗
14. Melarsoprol resistance in African trypanosomiasis10.1016/j.pt.2018.04.002 ↗
15. Drug resistance in nematodes of veterinary importance: a status report10.1016/j.pt.2004.08.001 ↗
16. Absorption, distribution, metabolism and excretion of the biomaterials used in nanocarrier drug delivery systems10.1016/j.addr.2019.06.008 ↗
17. Current research trends of nanomedicines10.1016/j.apsb.2023.05.018 ↗
18. Metallic nanoparticles and core-shell nanosystems in the treatment, diagnosis, and prevention of parasitic diseases10.3390/pathogens12060838 ↗
19. Malaria: past, present, and future10.1038/s41392-025-02246-3 ↗
20. Comprehensive insights into leishmaniasis: from etiopathogenesis to a novel therapeutic approach10.1016/j.micpath.2025.107535 ↗
21. An updated view of the Trypanosoma cruzi life cycle: intervention points for an effective treatment10.1021/acsinfecdis.2c00123 ↗
22. Application of microphysiological systems to unravel the mechanisms of schistosomiasis egg extravasation10.3389/fcimb.2025.1521265 ↗
23. Decoding the complexities of human malaria through systems immunology10.1111/imr.12817 ↗
24. Current challenges and nanotechnology-based pharmaceutical strategies for the treatment and control of malaria10.1016/j.parepi.2022.e00244 ↗
25. Advances in leishmaniasis10.1016/S0140-6736(05)67629-5 ↗
26. Cutaneous Leishmaniasis caused by Leishmania infantum , Israel, 2018–202110.3201/eid2905.221812 ↗
27. Biogenic metal nanoparticles as A potential class of antileishmanial agents: mechanisms and molecular targets10.2217/nnm-2019-0413 ↗
28. Targeting Leishmania infantum mannosyl-oligosaccharide glucosidase with natural products: potential pH-dependent inhibition explored through computer-aided drug design10.3389/fphar.2024.1403203 ↗
29. Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations10.1093/jac/dkaf473 ↗
30. Targeting the nucleotide metabolism of Trypanosoma brucei and other trypanosomatids
31. Human African trypanosomiasis10.1016/S0140-6736(17)31510-6 ↗
32. Nanotechnological interventions for treatment of trypanosomiasis in humans and animals10.1007/s13346-020-00764-x ↗
33. Treatment options for second-stage gambiense human African trypanosomiasis10.1586/14787210.2014.959496 ↗
34. Human African trypanosomiasis10.1016/S0140-6736(25)00107-2 ↗
35. Chagas disease10.1016/S0140-6736(17)31612-4 ↗
36. 2022
37. Freshwater snail-borne parasitic diseases in Africa10.1186/s41182-024-00632-1 ↗
38. A comprehensive exploration of schistosomiasis: global impact, molecular characterization, drug discovery, artificial intelligence and future prospects10.1016/j.heliyon.2024.e33070 ↗
39. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis10.1186/1756-3305-4-201 ↗
40. In vivo evaluation of an antibody-functionalized lipoidal nanosystem for schistosomiasis intervention10.3390/pharmaceutics14081531 ↗
41. Progress and challenges in bacterial infection theranostics based on functional metal nanoparticles10.1016/j.cis.2024.103265 ↗
42. Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases10.1080/14760584.2020.1758070 ↗
43. Application of silver nanoparticles in parasite treatment10.3390/pharmaceutics15071783 ↗
44. Biological synthesis of copper nanoparticles using edible plant allium monanthum: characterization of antibacterial, antioxidant, and anti-inflammatory properties using in silico molecular docking analysis10.3390/ma16206669 ↗
45. Biosynthesis and extrinsic toxicity of copper oxide nanoparticles against cattle parasites: an eco-friendly approach10.1016/j.envres.2022.114009 ↗
46. Zinc oxide nanoparticles produced by Zingiber officinale ameliorates acute toxoplasmosis-induced pathological and biochemical alterations and reduced parasite burden in mice model10.1371/journal.pntd.0011447 ↗
47. A review on the synthesis and functionalization of gold nanoparticles as a drug delivery vehicle10.2147/IJN.S279094 ↗
48. Size-dependent cytotoxicity of silver nanoparticles in human lung cells: the role of cellular uptake, agglomeration and Ag release10.1186/1743-8977-11-11 ↗
49. In vivo testing of gold nanoparticles using the Caenorhabditis elegans model organism10.1016/j.actbio.2017.01.080 ↗
50. Agglomeration of Escherichia coli with positively charged nanoparticles can lead to artifacts in a standard Caenorhabditis elegans toxicity assay10.1021/acs.est.7b06099 ↗
51. Biogenesis of metal nanoparticles and their pharmacological applications: present status and application prospects10.1007/s40097-018-0267-4 ↗
52. Biological synthesis of nanoparticles from plants and microorganisms10.1016/j.tibtech.2016.02.006 ↗
53. Critical antileishmanial in vitro effects of highly examined gold nanoparticles10.2147/IJN.S268548 ↗
54. The antimicrobial activity of nanoparticles: present situation and prospects for the future10.2147/IJN.S121956 ↗
55. Targeting and inhibiting Plasmodium falciparum using ultra-small gold nanoparticles10.1021/acsami.0c09075 ↗
56. Pre-clinical study of iron oxide nanoparticles fortified artesunate for efficient targeting of malarial parasite10.1016/j.ebiom.2019.06.026 ↗
57. ZIF-8 with encapsulated dihydroartemisinin in a drug delivery system for protection against Plasmodium berghei ANKA-Induced experimental cerebral malaria in C57BL/6N mice
58. Enhanced antimalarial efficacy obtained by targeted delivery of artemisinin in heparin-coated magnetic hollow mesoporous nanoparticles10.1021/acsami.0c20070 ↗
59. Biofunctionalized Chrysin-conjugated gold nanoparticles neutralize leishmania parasites with high efficacy10.1016/j.ijbiomac.2022.02.047 ↗
60. Potential therapeutic effects of curcumin coated silver nanoparticle in the treatment of cutaneous leishmaniasis due to Leishmania major in-vitro and in a murine model
61. The therapeutic effects of curcumin-coated gold nanoparticle against Leishmania major causative agent of Zoonotic Cutaneous Leishmaniasis (ZCL): an in vitro and in vivo study10.1007/s00284-022-03172-1 ↗
62. Amphotericin-B-loaded polymer-functionalized reduced graphene oxides for Leishmania amazonensis chemo-photothermal therapy10.1016/j.colsurfb.2021.112169 ↗
63. The synergistic anti-leishmanial effect of photodynamic therapy employing chemotherapy-mediated nanocomposites10.1038/s41598-025-01097-w ↗
64. Gold nanoparticle-based conjugated nanotags as potential compounds against Trypanosoma brucei infection10.1021/acsanm.4c05201 ↗
65. Plant-mediated biosynthesis of nanoparticles as an emerging tool against mosquitoes of medical and veterinary importance: a review10.1007/s00436-015-4800-9 ↗
66. Nanobiotechnology as an emerging approach to combat malaria: a systematic review10.1016/j.nano.2019.02.017 ↗
67. Anti-malarial activity of nano tannic acid MgO extract alone and combined with chloroquine against Plasmodium berghei10.18502/jad.v18i3.18577 ↗
68. Tri-metallic (Au–Pt–Ag) nanofluids: unveiling synergistic anti-malarial, cytotoxic, and antioxidant potentials through experimental and computational approaches10.1039/D5RA02037A ↗
69. Kaya, kaya, rafailovich, antileishmanial effect of silver nanoparticles and their enhanced antiparasitic activity under ultraviolet light10.2147/IJN.S23883 ↗
70. Nano-based antileishmanial agents: a toxicological study on nanoparticles for future treatment of cutaneous leishmaniasis10.1016/j.tiv.2013.06.002 ↗
71. Lectin coated MgO nanoparticle: its toxicity, antileishmanial activity, and macrophage activation10.3109/01480545.2013.870192 ↗
72. Biogenic gold nanoparticles against wild and resistant type visceral leishmaniasis10.1016/j.matpr.2018.01.086 ↗
73. Zinc nanoparticles coated with peppermint (Mentha piperita) essential oil: a nanoformulated compound with anti-leishmanial activity10.1007/s12639-024-01741-8 ↗
74. Gold–Silver bimetallic nanoparticles reduced with herbal leaf extracts induce ROS-mediated death in both promastigote and amastigote stages of Leishmania donovani10.1021/acsomega.0c02032 ↗
75. Metal nanoparticles restrict the growth of protozoan parasites10.1080/21691401.2018.1489267 ↗
76. Interaction of metal nanoparticles with recombinant arginine kinase from Trypanosoma brucei: thermodynamic and spectrofluorimetric evaluation10.1016/j.bbagen.2013.10.038 ↗
77. Apoferritin and apoferritin-capped metal nanoparticles inhibit arginine kinase of Trypanosoma brucei10.3390/molecules25153432 ↗
78. Comparative analysis of the interaction of silver nanoparticles with hexokinase from Trypanosoma brucei and humans10.2147/IJN.S401319 ↗
79. Biogenic silver nanoparticle exhibits schistosomicidal activity in vitro and reduces the parasitic burden in experimental schistosomiasis mansoni10.1016/j.micinf.2023.105145 ↗
80. Molluscicidal and antioxidant activities of silver nanoparticles on the multi-species of snail intermediate hosts of schistosomiasis10.1371/journal.pntd.0010667 ↗
81. In situ preparation of Dehydrodieugenol‐Loaded silver nanoparticles and their antischistosomal activity10.1002/cbdv.202301929 ↗
82. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives10.3390/molecules27041372 ↗
83. Investigating the application of liposomes as drug delivery systems for the diagnosis and treatment of cancer10.1155/2021/3041969 ↗
84. Artificial and naturally derived phospholipidic bilayers as smart coatings of solid-state nanoparticles: current works and perspectives in cancer therapy
85. Injectable hydrogel based on liposome self-assembly for controlled release of small hydrophilic molecules10.1016/j.actbio.2024.05.044 ↗
86. Establishment and evaluation of glucose-modified nanocomposite liposomes for the treatment of cerebral malaria10.1186/s12951-022-01493-8 ↗
87. Enhanced anti-malarial efficacy of mefloquine delivered via cationic liposome in a murine model of experimental cerebral malaria10.1016/j.ejpb.2024.114210 ↗
88. A nanodrug coated with membrane from brain microvascular endothelial cells protects against experimental cerebral malaria10.1021/acs.nanolett.1c03514 ↗
89. Decoquinate liposomes: highly effective clearance of plasmodium parasites causing severe malaria10.1186/s12936-022-04042-8 ↗
90. Formulation of amphotericin B in PEGylated liposomes for improved treatment of cutaneous leishmaniasis by parenteral and oral routes10.3390/pharmaceutics14050989 ↗
91. Enhancing the therapeutic landscape of cutaneous leishmaniasis: pegylated liposomal delivery of miltefosine for controlled release and improved efficacy
92. Therapeutic efficacy of a mixed formulation of conventional and PEGylated liposomes containing meglumine antimoniate, combined with allopurinol, in dogs naturally infected with Leishmania infantum10.1128/AAC.00234-20 ↗
93. Nano-elastic liposomes as multidrug carrier of sodium stibogluconate and ketoconazole: a potential new approach for the topical treatment of cutaneous Leishmaniasis10.1016/j.ejps.2020.105256 ↗
94. Combination of the topical photodynamic therapy of Chloroaluminum Phthalocyanine liposomes with fexinidazole oral self-emulsifying system as a new strategy for cutaneous leishmaniasis treatment10.3390/pharmaceutics16040509 ↗
95. In vitro evaluation of aerosol therapy with pentamidine-loaded liposomes coated with chondroitin sulfate or heparin for the treatment of leishmaniasis10.3390/pharmaceutics15041163 ↗
96. Trypanocidal activity of liposomal isotretinoin and loratadine formulations
97. Anti-staphylococcal, antibiofilm and trypanocidal activities of CrataBL encapsulated into liposomes: Lectin with potential against infectious diseases10.1016/j.micpath.2024.107007 ↗
98. Comparative in vitro transportation of pentamidine across the blood-brain barrier using polycaprolactone nanoparticles and phosphatidylcholine liposomes, artificial cells
99. Liposomal-praziquantel: efficacy against Schistosoma mansoni in a preclinical assay10.1016/j.actatropica.2013.06.011 ↗
100. Liposomes for malaria management: the evolution from 1980 to 202010.1186/s12936-021-03858-0 ↗